European pharmaceutical product market entry is consistently underestimated in its execution complexity. Most companies enter with a strategy and fail on implementation — wrong partners, misaligned commercial models, regulatory timelines that miss launch windows, and GTM architectures that do not survive contact with local market reality.
Valthera exists to close the strategy to execution gap — taking responsibility for delivery, not just design, and ensuring that what is planned gets implemented and performs in-market.
We help companies build and own the commercial infrastructure that creates long-term value in Europe.
Valthera is built around a different model:
We work as part of your commercial team rather than advising from the outside. We take accountability for execution milestones, not just the quality of the document. When things need to change mid-execution, we are already inside the operation to change them.
Our market entry plans are operational documents, not strategy presentations. They define who does what, by when, and with what resources — and feed directly into execution.
We measure performance against commercial outcomes — first-year revenue, partner performance, launch timing, and market share trajectory — not against the volume of deliverables produced.